Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vivus Inc VVUSQ

Healthcare Biotechnology
VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic... see more

Recent & Breaking News (OTCPK:VVUSQ)

VIVUS Reports Second Quarter 2017 Financial Results

MarketWire Canada August 3, 2017

VIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation

Marketwired July 5, 2017

Biotech Stock Performance Review -- Vertex Pharma, VIVUS, Xbiotech, and Axovant Sciences

PR Newswire June 30, 2017

Thomas B. King Joins VIVUS' Board of Directors

MarketWire Canada May 24, 2017

How These Biotech Stocks are Faring? -- Seattle Genetics, Sangamo Therapeutics, Vertex Pharma, and VIVUS

PR Newswire May 15, 2017

VIVUS Reports 2017 First Quarter Financial Results

Marketwired May 3, 2017

Investor Network: VIVUS, Inc. to Host Earnings Call

Accesswire May 3, 2017

VIVUS Announces Date of 2017 First Quarter Business Update and Financial Results Teleconference

MarketWire Canada April 25, 2017

VIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi

MarketWire Canada March 27, 2017

Research Reports Coverage on Biotech Stocks -- VIVUS, Ultragenyx Pharma, Cymabay Therapeutics, and Omeros

PR Newswire March 17, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  March 9, 2017

Mid-Morning Market Update: Markets Edge Higher; Staples Earnings Miss Views

Benzinga.com  March 9, 2017

22 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  March 9, 2017

VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results

Marketwired March 8, 2017

VIVUS Announces Date of 2016 Fourth Quarter Business Update and Financial Results Teleconference

Marketwired February 28, 2017

Research Reports Coverage on Biotech Stocks -- Emergent BioSolutions, Chimerix, VIVUS, and RXi Pharma

PR Newswire January 18, 2017

VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH)

Marketwired January 9, 2017

VIVUS Reports 2016 Third Quarter Financial Results

MarketWire Canada November 9, 2016

Biotech Stocks on Investors' Radar -- Illumina, XOMA, Lexicon Pharma, and VIVUS

PR Newswire August 18, 2016

Biotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS

PR Newswire June 14, 2016